TRIMAZOSIN

Trimazosin is an alpha‑1 adrenergic blocker used for hypertension and urinary obstruction. It relaxes smooth muscle and lowers blood pressure. Side effects include dizziness, hypotension, nasal congestion, and fatigue.

SKU: 3cc3ff821b7b Category: Tag:

Product Description


Mechanism of Action

TRIMAZOSIN (ID 27751) demonstrates multi‑layer biochemical influence across signalling hierarchies, catalytic‑domain regulation, mitochondrial‑network energetics, ion‑gradient stability, membrane electrochemistry, redox equilibrium and transcription‑factor axis alignment. Its molecular topology enables interaction with catalytic residues, allosteric nodes, hydrophobic receptor microdomains, transmembrane helices, redox‑buffer matrices and cytoskeletal scaffolds, resulting in wide‑spectrum modulation across metabolic, structural, electrophysiological and genomic systems.

Mechanistically, TRIMAZOSIN may remodel phosphorylation flux across MAPK/ERK/JNK/p38 pathways, reshape PI3K–AKT survival topology, modify G‑protein coupling dynamics, reorganise Ca²⁺ signalling microdomains, influence IP₃/DAG cascade geometry and adjust cAMP–PKA amplitude distributions. Mitochondrial impacts include ETC‑complex rebalancing, ATP/ADP turnover pattern shifts, ROS‑threshold displacement, membrane‑potential polarity modulation and ER–mitochondrial stress‑cross‑talk regulation.

Advanced Research Applications

  • Kinome‑scale interference mapping and catalytic‑cascade simulation
  • High‑resolution docking and conformational‑transition modelling
  • UPR/ER‑stress, autophagy–mitophagy and organelle‑network integration research
  • Multi‑omics regulatory reconstruction (RNA‑seq, phosphoproteomics, metabolomics, proteomics)
  • Cytoskeletal tension‑mapping and polymer‑turnover analysis
  • Cell‑fate simulations (apoptosis, necroptosis, ferroptosis, parthanatos)
  • Machine‑learning SAR/QSAR predictive optimisation

Toxicodynamics & Hazard Profile

  • Accelerated ROS accumulation & antioxidant‑buffer saturation
  • Mitochondrial fragmentation or ETC‑axis destabilisation
  • Severe Na⁺/K⁺/Ca²⁺ ionic‑flux dysregulation
  • Cytoskeletal collapse & membrane‑integrity failure
  • Inflammatory‑axis hyperactivation (NF‑κB, STAT, IRF pathways)
  • Activation of multi‑axis programmed‑cell‑death pathways
  • Epigenetic methylation/acetylation drift

For expert laboratory research only — not intended for biological or therapeutic exposure.

Datasheet


Molecular Formula

C20H29N5O6

Molecular Weight

435.5 g/mol

CAS Number

35795-16-5

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

TRIMAZOSIN; 35795-16-5; Trimazosine; Trimazosinum; trimazosina

IUPAC/Chemical Name

(2-hydroxy-2-methylpropyl) 4-(4-amino-6,7,8-trimethoxyquinazolin-2-yl)piperazine-1-carboxylate

InChl Key

YNZXWQJZEDLQEG-UHFFFAOYSA-N

InChl Code

InChI=1S/C20H29N5O6/c1-20(2,27)11-31-19(26)25-8-6-24(7-9-25)18-22-14-12(17(21)23-18)10-13(28-3)15(29-4)16(14)30-5/h10,27H,6-9,11H2,1-5H3,(H2,21,22,23)

References

https://pubchem.ncbi.nlm.nih.gov/compound/37264;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download